Hypertension in FMR1 premutation males with and without fragile X-associated tremor/ataxia syndrome (FXTAS)
- PMID: 22528549
- PMCID: PMC3983689
- DOI: 10.1002/ajmg.a.35323
Hypertension in FMR1 premutation males with and without fragile X-associated tremor/ataxia syndrome (FXTAS)
Abstract
Fragile X-associated tremor ataxia syndrome (FXTAS) is a late onset neurodegenerative disease that affects carriers of the fragile X premutation. This study seeks to assess hypertension risk and susceptibility in male premutation carriers with FXTAS. Although many symptoms and diagnostic criteria have been identified, hypertension risk has not been examined in this population. Data from 92 premutation carriers without FXTAS, 100 premutation carriers with FXTAS, and 186 controls was collected via patient medical interview. Age-adjusted logistic regression analysis was used to examine the relative odds of hypertension. We observed a significantly elevated odds ratio (OR) of hypertension relative to controls for premutation carriers with FXTAS (OR = 3.22, 95% CI: 1.72-6.04; P = 0.0003) among participants over 40-year old. The age-adjusted estimated odds of hypertension in premutation carriers without FXTAS in the over 40-year-old age group was higher compared to controls (OR = 1.61, 95% CI: 0.82-3.16), but was not statistically significant (P = 0.164). Chronic hypertension contributes to cardiovascular complications, dementia, and increased risk of stroke. Our results indicate that the risk of hypertension is significantly elevated in male premutation carriers with FXTAS compared with carriers without FXTAS and controls. Thus, evaluation of hypertension in patients diagnosed with FXTAS should be a routine part of the treatment monitoring and intervention for this disease.
Copyright © 2012 Wiley Periodicals, Inc.
Conflict of interest statement
Conflict of interest: Dr. Hagerman’s work has been funded by the NIH. Other funding has been received for clinical trials from Seaside Therapeutics, Roche Pharmaceuticals, Novartis, Forest, and Curemark. Other authors declare no potential conflict of interest.
References
-
- Adams JS, Adams PE, Nguyen D, Brunberg JA, Tassone F, Zhang W, Koldewyn K, Rivera SM, Grigsby J, Zhang L, DeCarli C, Hagerman PJ, Hagerman RJ. Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS) Neurology. 2007;69:851–859. - PubMed
-
- Bacalman S, Farzin F, Bourgeois JA, Cogswell J, Goodlin-Jones BL, Gane LW, Grigsby J, Leehey MA, Tassone F, Hagerman RJ. Psychiatric phenotype of the fragile X-associated tremor/ataxia syndrome (FXTAS) in males: Newly described fronto-subcortical dementia. J Clin Psychiatry. 2006;67:87–94. - PubMed
-
- Berry-Kravis E, Abrams L, Coffey SM, Hall DA, Greco C, Gane LW, Grigsby J, Bourgeois JA, Finucane B, Jacquemont S, Brunberg JA, Zhang L, Lin J, Tassone F, Hagerman PJ, Hagerman RJ, Leehey MA. Fragile X-associated tremor/ataxia syndrome: Clinical features, genetics, and testing guidelines. Mov Disord. 2007;22:2018–2030. - PubMed
-
- Berry-Kravis E, Hall DA, Leehey MA, Hagerman RJ. Treatment and management of FXTAS. In: Tassone F, Berry-Kravis E, editors. The fragile X-associated tremor ataxia syndrome (FXTAS) New York: Springer; 2010. pp. 137–154.
Publication types
MeSH terms
Substances
Grants and funding
- 90DD05969/DD/NCBDD CDC HHS/United States
- UL1 DE019583/DE/NIDCR NIH HHS/United States
- HD02274/HD/NICHD NIH HHS/United States
- AG032119/AG/NIA NIH HHS/United States
- RL1 AG032119/AG/NIA NIH HHS/United States
- HD036071/HD/NICHD NIH HHS/United States
- R01 HD036071/HD/NICHD NIH HHS/United States
- AG032115/AG/NIA NIH HHS/United States
- P30 HD002274/HD/NICHD NIH HHS/United States
- R01 MH078041/MH/NIMH NIH HHS/United States
- MH078041/MH/NIMH NIH HHS/United States
- DA024854/DA/NIDA NIH HHS/United States
- TL1 DA024854/DA/NIDA NIH HHS/United States
- UL1 RR024146/RR/NCRR NIH HHS/United States
- RL1 AG032115/AG/NIA NIH HHS/United States
- DE019583/DE/NIDCR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical